Through the optimization of the active metabolite 2 of the piperidine derivative 1, we discovered a potent new drug candidate for the treatment of RA, Y-320 that inhibits T cell activation induced by IL-15 and shows a therapeutic effect on collagen-induced arthritis in DBA/1J mice. Design and structure-activity relationships are described.
Keywords: Y-320, IL-15, Phenylpyrazoleanilide, RA, CIA
open access plus
Rights & PermissionsPrintExport